Articles tagged "Heart transplant patients"

2017 American Transplant Congress
Alemtuzumab Use in a Single Center Pediatric Heart Transplant Cohort.
J. Case,¹ J. Eshelman,² P. Booker,² S. Miyamoto,³ M. Everitt,³ S. Auerbach.³
¹University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO; ²Pharmacy, Children's Hospital Colorado, Aurora, CO; ³Pediatrics, Division of Cardiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO
Purpose: To describe the use and complications of alemtuzumab (AMB), a CD52 monoclonal antibody, in pediatric heart transplant (HT) patients (pt).Methods: Retrospective chart review of…
2017 American Transplant Congress
Time to First Therapeutic Tacrolimus Level: What Impact Does It Have After Heart Transplantation?
O. Witkowsky, J. Teuteberg, C. Sciortino, M. Shullo.
University of Pittsburgh Medical Center, Pittsburgh, PA
Purpose: Appropriate time to therapeutic immunosuppression levels is not well defined. The purpose of this study is to investigate outcomes related to time to therapeutic…
2017 American Transplant Congress
Exploring Differential Antibody Response to Bortezomib in Heart Transplantation.
K. Ghafourian, R. Hod-Dvorai, S. McCabe, N. Cool, M. Fine, M. Ackerman, J. Rich, J. Wilcox, E. Vorovich, A. Anderson, A. Tambur.
Northwestern University, Chicago, IL
Twelve heart transplant candidates (2013-2016) received Bortezomib (BTZ) for desensitization. Differential antibody (Ab) response was observed. BTZ cycles consisted of 4 injections of 1.3 mg/m2;…
2016 American Transplant Congress
Predictors of Donor Heart Utilization in United States.
J. Trivedi, A. Cheng, E. Schumer, M. Black, H. Massey, M. Slaughter.
Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY.
BackgroundOptimum use of donor organs can increase the reach of the transplant therapy to more patients on waitlist. The heart transplant (HTx) has remained stagnant…
2016 American Transplant Congress
Four-Factor Prothrombin Complex Concentrate as a Strategy to Rapidly Reverse Anticoagulation in Patients Undergoing Cardiac Transplantation: Better Than the Conventional Approach?
T. Sam,¹ G. Gonzalez-Stawinski,² G. Saracino,³ A. Jamil,³ S. Hall,² K. Cox,¹ B. Lima.²
¹Department of Pharmacy, Baylor University Medical Center, Dallas, TX; ²Heart Transplantation and Mechanical Circulatory Support, Baylor University Medical Center, Dallas, TX; ³Baylor Research Institute, Baylor University Medical Center, Dallas, TX.
PurposeThe purpose of this analysis is to compare outcomes of administering four-factor prothrombin complex concentrate (4F-PCC, Kcentra™) versus standard of care for anticoagulation reversal in…
2016 American Transplant Congress
The Impact of Donor Origin on Survival after Orthotopic Heart Transplantation.
O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma.
University of British Columbia, Vancouver, BC, Canada.
BackgroundOrthotopic heart transplantation (OHT) is the gold standard for the management of select patients with end-stage heart failure, but limited by an ongoing organ donor…
2016 American Transplant Congress
Using Gastrointestinal Biopsy to Predict Outcome in Patients Evaluated for Cardiac Transplantation for Amyloidosis: A Report from the International Consortium on Cardiac Amyloidosis Transplantation (iCCAT).
Y. Li,¹ K. Verkouw,¹ S. Tabtabai,¹ R. Barrios,² R. Gill,³ J. Koo,⁴ C. Marboe,⁵ E. Rodriguez,⁶ C. Tan,⁶ T. De Marco,³ J. Estep,² M. Hanna,⁶ M. Maurer,⁵ J. Patel,⁴ V. Selby,³ M. Semigran,¹ J. Stone.¹
¹Massachusetts General Hospital, Boston, MA; ²The Methodist Hospital, Houston, TX; ³University of California San Francisco, San Francisco, CA; ⁴Cedars-Sinai Heart Institute, Los Angeles, CA; ⁵Columbia University Medical Center, New York, NY; ⁶Cleveland Clinic, Cleveland, OH.
Heart transplant (HT) is an established therapy for heart failure due to amyloidosis. The utility of gastrointestinal (GI) biopsy in predicting patient outcomes and guiding…
2016 American Transplant Congress
Exosomes Expressing Cardiac Self-Antigens (Myosin and Vimentin) and Immuno-Regulatory miRNA Induce Graft Rejection.
M. Sharma,^1,2 M. Gunasekaran,^1,2 Z. Xu,^1,2 N. Steward,¹ W. Liu,^1,2 N. Benshoff,¹ T. Mohanakumar.^1,2
¹Washington Univ Sch Med, St. Louis, MO; ²Norton Thoracic Institute - St. Joseph's Hospital, Phoenix, AZ.
Heart transplantation (HTx) remains an option for patients with cardiac diseases. However, humoral and cell mediated immune responses represent a major obstacle for long-term survival.…
2016 American Transplant Congress
Air Pollution – An Additional Risk Factor for Developing Cardiac Allograft Vasculopathy.
C. Bara, D. Böthig, Y. Scheibner, D. Bobylev, B. Przybylek, A. Haverich.
Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Purpose:Cardiac allograft vasculopathy (CAV) remains one of the primary causes of death in long-term follow-up after heart transplantation (HTx) and is the most limiting factor…
2016 American Transplant Congress
Impact of Transfusion Requirements on Likelihood of Heart Transplantation After Total Artificial Heart.
J. Cook,¹ L. Kang,¹ M. Flattery,² I. Tchoukina.²
¹Internal Medicine, Virginia Commonwealth University, Richmond, VA; ²Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
Background:Total artificial heart (TAH) is used as a bridge to heart transplantation in patients with end-stage biventricular failure. Anemia requiring blood transfusions occurs following TAH…